Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab (HLX10) plus Chemotherapy in Advanced Cervical Cancer
NCT04806945Phase 3Withdrawn
- Sponsor
- Henlius
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in Cervical Cancer (CC), sponsored by Henlius. Planned start Sep 2022; status: withdrawn.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04806945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806945.